CLRB (Cellectar Biosciences) Total Long-Term Assets: $1.85 Mil (As of Mar. 2026)


CLRB Cellectar Biosciences Inc CLRB
23 GF Score
Price $2.69
! 1 Warning Sign
View Full Analysis

What is Cellectar Biosciences Total Long-Term Assets?

Cellectar Biosciences CLRB -2.18% 23 Total Long-Term Assets is $1.85 Mil as of Mar. 2026. GuruFocus rates CLRB with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Cellectar Biosciences's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $1.85 Mil.

Cellectar Biosciences Total Long-Term Assets Related Terms

Cellectar Biosciences Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Cellectar Biosciences's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectar Biosciences Total Long-Term Assets Chart

Cellectar Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 1.06 1.62 1.22 0.94

Cellectar Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 1.08 1.01 0.94 1.85
CLRB
23GF Score
Cellectar Biosciences Inc CLRB
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectar Biosciences Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $1.85 Mil mean?
Cellectar Biosciences (CLRB) has a Total Long-Term Assets of $1.85 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Cellectar Biosciences and its competitors.
Is Cellectar Biosciences' Total Long-Term Assets too high?
Cellectar Biosciences' current Total Long-Term Assets is $1.85 Mil. Overall, Cellectar Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' Total Long-Term Assets compare to OTLC and PTN?
Cellectar Biosciences' Total Long-Term Assets of $1.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Cellectar Biosciences and its competitors. Cellectar Biosciences's current Total Long-Term Assets is $1.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current Total Long-Term Assets of $1.85 Mil. The current Total Long-Term Assets is $1.85 Mil. Cellectar Biosciences' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current Total Long-Term Assets is $1.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellectar Biosciences Business Description

Address 100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
23GF Score

Get the complete analysis for CLRB

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.69
Price